Cardiovascular risk in PsA greater for new users of IL-12/23, IL-17 vs. TNF inhibitors

cardiovascular risk in psa greater for new users of il 12 23 il 17 vs tnf inhibitors

Sumary of Cardiovascular risk in PsA greater for new users of IL-12/23, IL-17 vs. TNF inhibitors:

  • July 22, 2021 2 min read Source/Disclosures Published by: Disclosures: Vegas reports no relevant financial disclosures.
  • ” To analyze the risk for major adverse cardiovascular events in patients with PsA using various classes of biologic DMARDs and apremilast (Otezla, Amgen), Vegas and colleagues conducted a nationwide cohort study based on health administrative data from the French National Health Insurance.
  • According to the researchers, the national health insurance system covers approximately 67 million people in France and is linked with the national hospital discharge database.
  • The primary endpoint was major adverse cardiovascular events, with the researchers using a time-to-event analysis with propensity score-weighted Cox and Fine-Gray models.
  • Vegas and colleagues reported similar results in the Fine-Gray competing-risks survival model.

Want to know more click here go to source.

From -

Generic selectors
Exact matches only
Search in title
Search in content

Site Language

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.